New Prognostic and Predictive Markers in Cancer Progression

Biomarkers are of critical medical importance for oncologists, allowing them to predict and detect disease and to determine the best course of action for cancer patient care. Prognostic markers are used to evaluate a patient’s outcome and cancer recurrence probability after initial interventions suc...

Full description

Saved in:
Bibliographic Details
HerausgeberIn:
Sonstige:
Year of Publication:2021
Language:English
Physical Description:1 electronic resource (294 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
id 993546334004498
ctrlnum (CKB)5400000000045439
(oapen)https://directory.doabooks.org/handle/20.500.12854/68373
(EXLCZ)995400000000045439
collection bib_alma
record_format marc
spelling Costantini, Susan edt
New Prognostic and Predictive Markers in Cancer Progression
Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021
1 electronic resource (294 p.)
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
Biomarkers are of critical medical importance for oncologists, allowing them to predict and detect disease and to determine the best course of action for cancer patient care. Prognostic markers are used to evaluate a patient’s outcome and cancer recurrence probability after initial interventions such as surgery or drug treatments and, hence, to select follow-up and further treatment strategies. On the other hand, predictive markers are increasingly being used to evaluate the probability of benefit from clinical intervention(s), driving personalized medicine. Evolving technologies and the increasing availability of “multiomics” data are leading to the selection of numerous potential biomarkers, based on DNA, RNA, miRNA, protein, and metabolic alterations within cancer cells or tumor microenvironment, that may be combined with clinical and pathological data to greatly improve the prediction of both cancer progression and therapeutic treatment responses. However, in recent years, few biomarkers have progressed from discovery to become validated tools to be used in clinical practice. This Special Issue comprises eight review articles and five original studies on novel potential prognostic and predictive markers for different cancer types.
English
Medicine bicssc
MSI2
OSCC
oral cancer
musashi 2
prognosis
N-cadherin
EMT
breast cancer
new metastasis
eribulin
blood
biomarker
bladder cancer
immune checkpoint inhibitor
CD8+ T effector cells
microRNA
biomarkers
head and neck cancer
laryngeal cancer
prediction
metastasis
lifestyle habit
chemo-/radio resistance
therapeutic target
AKT
AR
castration-resistant prostate cancer (CRPC)
MAPK
mTOR
PI3K
prostate cancer
therapeutic resistance
WNT
miRNA
melanoma
melanoma resistance to MAPK/MEK inhibitors
resistance to immune checkpoint inhibitors
TNBC
BRCA1/2
HRR
PDL1
TILs
PI3KCA
PTEN
CTCs
CSC
pancreatic cancer
K-RAS oncogene
oncogene dependency
targeted therapies
genomic mutations
transcriptomics
metabolomics
selenoproteins
cancer
HUB nodes
major histocompatibility complex (MHC)
human leukocyte antigen (HLA)
antigen processing machinery (APM) molecules
carcinogenesis
tumor predisposition
cancer immunotherapy
pheochromocytoma
paraganglioma
head and neck neoplasms
head and neck tumors
genetic syndromes
mutations
hyperglycemia
cardioncology
nivolumab
cytokines
cardiotoxicity
acetyltransferase
cancer prognosis
NAA10
3-03943-977-4
3-03943-978-2
Budillon, Alfredo edt
Costantini, Susan oth
Budillon, Alfredo oth
language English
format eBook
author2 Budillon, Alfredo
Costantini, Susan
Budillon, Alfredo
author_facet Budillon, Alfredo
Costantini, Susan
Budillon, Alfredo
author2_variant s c sc
a b ab
author2_role HerausgeberIn
Sonstige
Sonstige
title New Prognostic and Predictive Markers in Cancer Progression
spellingShingle New Prognostic and Predictive Markers in Cancer Progression
title_full New Prognostic and Predictive Markers in Cancer Progression
title_fullStr New Prognostic and Predictive Markers in Cancer Progression
title_full_unstemmed New Prognostic and Predictive Markers in Cancer Progression
title_auth New Prognostic and Predictive Markers in Cancer Progression
title_new New Prognostic and Predictive Markers in Cancer Progression
title_sort new prognostic and predictive markers in cancer progression
publisher MDPI - Multidisciplinary Digital Publishing Institute
publishDate 2021
physical 1 electronic resource (294 p.)
isbn 3-03943-977-4
3-03943-978-2
illustrated Not Illustrated
work_keys_str_mv AT costantinisusan newprognosticandpredictivemarkersincancerprogression
AT budillonalfredo newprognosticandpredictivemarkersincancerprogression
status_str n
ids_txt_mv (CKB)5400000000045439
(oapen)https://directory.doabooks.org/handle/20.500.12854/68373
(EXLCZ)995400000000045439
carrierType_str_mv cr
is_hierarchy_title New Prognostic and Predictive Markers in Cancer Progression
author2_original_writing_str_mv noLinkedField
noLinkedField
noLinkedField
_version_ 1796651979343134720
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04583nam-a2201225z--4500</leader><controlfield tag="001">993546334004498</controlfield><controlfield tag="005">20231214133144.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202105s2021 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000045439</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/68373</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000045439</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Costantini, Susan</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">New Prognostic and Predictive Markers in Cancer Progression</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel, Switzerland</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2021</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (294 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Biomarkers are of critical medical importance for oncologists, allowing them to predict and detect disease and to determine the best course of action for cancer patient care. Prognostic markers are used to evaluate a patient’s outcome and cancer recurrence probability after initial interventions such as surgery or drug treatments and, hence, to select follow-up and further treatment strategies. On the other hand, predictive markers are increasingly being used to evaluate the probability of benefit from clinical intervention(s), driving personalized medicine. Evolving technologies and the increasing availability of “multiomics” data are leading to the selection of numerous potential biomarkers, based on DNA, RNA, miRNA, protein, and metabolic alterations within cancer cells or tumor microenvironment, that may be combined with clinical and pathological data to greatly improve the prediction of both cancer progression and therapeutic treatment responses. However, in recent years, few biomarkers have progressed from discovery to become validated tools to be used in clinical practice. This Special Issue comprises eight review articles and five original studies on novel potential prognostic and predictive markers for different cancer types.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">MSI2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">OSCC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oral cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">musashi 2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prognosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">N-cadherin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">EMT</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">breast cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">new metastasis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">eribulin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">blood</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biomarker</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bladder cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune checkpoint inhibitor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CD8+ T effector cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">microRNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biomarkers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">head and neck cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">laryngeal cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prediction</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metastasis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lifestyle habit</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chemo-/radio resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">therapeutic target</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">AKT</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">castration-resistant prostate cancer (CRPC)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">MAPK</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mTOR</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PI3K</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prostate cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">therapeutic resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">WNT</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">miRNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">melanoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">melanoma resistance to MAPK/MEK inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">resistance to immune checkpoint inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">TNBC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">BRCA1/2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HRR</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PDL1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">TILs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PI3KCA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PTEN</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CTCs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CSC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pancreatic cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">K-RAS oncogene</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oncogene dependency</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">targeted therapies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">genomic mutations</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">transcriptomics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metabolomics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">selenoproteins</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HUB nodes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">major histocompatibility complex (MHC)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">human leukocyte antigen (HLA)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antigen processing machinery (APM) molecules</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">carcinogenesis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor predisposition</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pheochromocytoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">paraganglioma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">head and neck neoplasms</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">head and neck tumors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">genetic syndromes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mutations</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">hyperglycemia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cardioncology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nivolumab</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cytokines</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cardiotoxicity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">acetyltransferase</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer prognosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NAA10</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03943-977-4</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03943-978-2</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Budillon, Alfredo</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Costantini, Susan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Budillon, Alfredo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:44:29 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&amp;portfolio_pid=5338232780004498&amp;Force_direct=true</subfield><subfield code="Z">5338232780004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338232780004498</subfield></datafield></record></collection>